drugset / Trial / NCT01909752
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
Phase 2
Completed
12 enrolled
UbiVac
Louisiana State University Health Sciences Center in New Orleans · collabMayo Clinic · collabNational Cancer Institute (NCI) · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collabProvidence Health & Services · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor.
Timeline
- Start
- 2013-07
- Primary completion
- 2016-11
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DRibble vaccine | Vaccine | — | — |
| Subject | Imiquimod | Other / unclassified | 12.5 mg | Topical |
| Subject | sargramostim | Protein / enzyme biologic | 50 ug | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Gardasil | Vaccine | 0.5 ml | Intramuscular |